Thanks for that. It is a very relevant article because it won't be the "rats and mice" pharma + biotechs that Fund Managers will start buying.
They will look to buy into the high quality ones.
Once sentiment turns positive in the biotech sector, you can expect PXS to be re-rated given that NOTHING fundamental has changed between 400c and 150c (I know the 2nd Phase II trial is fundamental but the company had forewarned of this for some time - although I didn't fully understand this fact myself at the time).
Coop
platinum, page-2
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
